本文選題：頭孢曲松鈉 + 胸腺五肽　； 參考：《中國(guó)地方病防治雜志》2017年03期

【摘要】：目的分析頭孢曲松鈉聯(lián)合胸腺五肽治療早期宮頸癌合并梅毒的效果。方法 100例早期宮頸癌合并梅毒患者按治療方案不同用雙盲法分為對(duì)照組(青霉素鈉聯(lián)合芐星青霉素)和觀察組(頭孢曲松鈉聯(lián)合胸腺五肽)。記錄治療1周患者皮損消退率,治療前及治療2周后血清T細(xì)胞水平;以12、24、48周為時(shí)間點(diǎn)對(duì)比兩組快速血漿反應(yīng)素環(huán)狀卡片實(shí)驗(yàn)(RPR)轉(zhuǎn)陰率、梅毒復(fù)發(fā)率、梅毒治療有效率;記錄0.5、1年生存率。結(jié)果 1周時(shí)觀察組皮損消率高于對(duì)照組;治療2周時(shí)CD4+和CD3+高于對(duì)照組,CD8+低于對(duì)照組;12、24、18周RPR轉(zhuǎn)陰率均高于對(duì)照組,梅毒復(fù)發(fā)3例低于對(duì)照組,梅毒治療有效率高于對(duì)照組;1年生存率高于對(duì)照組(P均0.05)。結(jié)論頭孢曲松鈉聯(lián)合胸腺五肽治療早期宮頸癌合并梅毒能快速消退皮損,改善T細(xì)胞水平,近期能提高RPR轉(zhuǎn)陰率,降低梅毒復(fù)發(fā)率,能提高1年生存率。
[Abstract]:Objective to analyze the effect of ceftriaxone sodium combined with thymic pentapeptide in the treatment of early cervical cancer with syphilis.Methods 100 patients with early cervical cancer complicated with syphilis were divided into two groups: control group (penicillin sodium combined with benzylpenicillin) and observation group (ceftriaxone sodium combined with thymopeptide).The regression rate of skin lesion, the serum T cell level before treatment and 2 weeks after treatment were recorded, and the rapid plasma RPR-negative rate, the recurrence rate of syphilis and the effective rate of syphilis treatment were compared between the two groups.The 0.5 and 1 year survival rates were recorded.Results the skin lesion elimination rate in the observation group was higher than that in the control group at 1 week, the CD4 and CD3 were higher in the observation group than in the control group at 2 weeks after treatment, and the RPR negative rate in the control group at 18 weeks was lower than that in the control group.The effective rate of syphilis treatment was higher than that of control group, and the 1 year survival rate was higher than that of control group (P < 0.05).Conclusion Ceftriaxone sodium combined with thymic pentapeptide in the treatment of early cervical cancer with syphilis can quickly dissipate lesions, improve T cell level, increase RPR negative rate, reduce syphilis recurrence rate and improve 1 year survival rate in the near future.
【作者單位】： 鄂爾多斯婦產(chǎn)醫(yī)院;鄂爾多斯市干部保健中心;
【基金】：深圳市醫(yī)學(xué)科研項(xiàng)目(編號(hào):200603116)
【分類(lèi)號(hào)】：R737.33;R759.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張豐林;;胸腺五肽治療惡性腫瘤患者的免疫指標(biāo)初探[J];傳染病信息;2000年01期

2 張緒清,王宇明,毛青,向德棟,馬巧玉;胸腺五肽治療慢性重型乙型病毒性肝炎的療效評(píng)價(jià)[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2003年22期

3 周紅華,馬仁玲,黃海燕,濮社班,盛龍生;胸腺五肽一級(jí)結(jié)構(gòu)的電噴霧質(zhì)譜分析[J];西北藥學(xué)雜志;2004年06期

4 鐘暉東;李斌;陳偉強(qiáng);;胸腺五肽對(duì)老年重型腦損害病人T淋巴細(xì)胞亞群的影響[J];廣東微量元素科學(xué);2006年06期

5 金j;魏剛;陸偉躍;;胸腺五肽溶液穩(wěn)定性考察[J];中國(guó)醫(yī)藥工業(yè)雜志;2007年10期

6 艾國(guó);梅興國(guó);;胸腺五肽微球體外釋放度的加速試驗(yàn)方法研究(英文)[J];Journal of Chinese Pharmaceutical Sciences;2008年01期

7 陳君;龐杰;張春彥;許楠;;胸腺五肽配合治療慢性阻肺38例療效觀察[J];中國(guó)民族民間醫(yī)藥;2009年02期

8 鄭愛(ài)萍;王堅(jiān)成;張p，

本文編號(hào)：1771082